Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

País/Região como assunto
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
World J Surg Oncol ; 22(1): 138, 2024 May 25.
Artigo em Inglês | MEDLINE | ID: mdl-38789966

RESUMO

BACKGROUND: The Catalan Cancer Plan (CCP) undertakes periodic audits of cancer treatment outcomes, including organ/space surgical site infections (O/S-SSI) rates, while the Catalan Healthcare-associated Infections Surveillance Programme (VINCat) carries out standardized prospective surveillance of surgical site infections (SSI) in colorectal surgery. This cohort study aimed to assess the concordance between these two monitoring systems for O/S-SSI following primary rectal cancer surgery. METHODS: The study compared O/S-SSI incidence data from CCP clinical audits versus the VINCat Programme in patients undergoing surgery for primary rectal cancer, in 2011-12 and 2015-16, in publicly funded centres in Spain. The main outcome variable was the incidence of O/S-SSI in the first 30 days after surgery. Concordance between the two registers was analysed using Cohen's kappa. Discordant cases were reviewed by an expert, and the main reasons for discrepancies evaluated. RESULTS: Pooling data from both databases generated a sample of 2867 patients. Of these, O/S-SSI was detected in 414 patients-235 were common to both registry systems, with satisfactory concordance (κ = 0.69, 95% confidence interval 0.65-0.73). The rate of discordance from the CCP (positive cases in VINCat and negative in CCP) was 2.7%, and from VINCat (positive in CCP and negative in VINCat) was 3.6%. External review confirmed O/S-SSI in 66.2% of the cases in the CCP registry and 52.9% in VINCat. CONCLUSIONS: This type of synergy shows the potential of pooling data from two different information sources with a satisfactory level of agreement as a means to improving O/S-SSI detection. CLINICALTRIALS: gov Identifier: NCT06104579. Registered 30 November 2023.


Assuntos
Neoplasias Retais , Infecção da Ferida Cirúrgica , Humanos , Neoplasias Retais/cirurgia , Masculino , Feminino , Infecção da Ferida Cirúrgica/epidemiologia , Infecção da Ferida Cirúrgica/diagnóstico , Infecção da Ferida Cirúrgica/etiologia , Espanha/epidemiologia , Idoso , Estudos Prospectivos , Pessoa de Meia-Idade , Sistema de Registros/estatística & dados numéricos , Seguimentos , Prognóstico , Incidência , Vigilância da População/métodos , Bases de Dados Factuais
2.
Clin Transl Radiat Oncol ; 45: 100717, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38226026

RESUMO

Background and purpose: The aim of this study was to review the published studies on the utilisation of radiotherapy in lung cancer (both small and non-small cell lung cancer, SCLC and NSCLC) patients in European countries with a population-based perspective. Material and methods: A literature search since January 2000 until December 2022 was carried out. Only English-published papers were included, and only European data was considered. PRISMA guidelines were followed. A scoping narrative review was undertaken due to the hetereogeneity of the published papers. Results: 38 papers were included in the analysis, with the majority from the Netherlands (52.6%) and the UK (18.4%). Large variability is observed in the reported radiotherapy utilisation, around 40% for NSCLC in general and between 26 and 42% in stage I NSCLC. Stereotactic body radiotherapy (SBRT) shows a wide range of utilisation across countries and over time, from 8 to 63%. Similary, in stage III lung cancer, chemoradiotherapy (CRT) utilisation varied considerably (11-70%). Eleven studies compared radiotherapy utilisation between older and younger age-groups, showing that younger patients receive more CRT, while the opposite applies for SBRT. An widespreadlack of data on relevant covariates such as comorbidty and health-services related variables is observed. Conclusion: The actual utilisation of radiotherapy for lung cancer reported in patterns-of-care studies (POCs) is notably lower than the evidence-based optimal utilisation. Important variability is observed by country, time period, stage at diagnosis and age. A wider use of POCs should be promoted to improve our knowledge on the actual application of evidence-based treatment recommendations.

3.
Salud pública Méx ; 44(supl.1): s11-s19, 2002. graf, tab
Artigo em Espanhol | LILACS | ID: lil-464227

RESUMO

El tabaco es la causa de mortalidad prevenible más importante en los países europeos, en los que da cuenta de más de medio millón de muertes anuales. El objetivo de este trabajo es revisar la epidemiología del tabaquismo en Europa, atendiendo a la visión de conjunto sobre el impacto del tabaquismo, a la prevalencia del consumo y a su evolución en la última década, así como revisar otras características relacionadas con la difusión y mantenimiento del tabaquismo: la producción y los precios del tabaco. Treinta de cada 100 europeos adultos fuma cigarrillos a diario. En los países de la Unión Europea se estima que 1 de cada 10 adultos fumadores morirá a causa de los efectos del tabaco, razón que se eleva a 1 de cada 5 en los países del este de Europa. La prevalencia de fumadores desciende entre los hombres adultos en algunos países de la Unión Europea, mientras que aumenta en las mujeres, sobre todo jóvenes, del sur y del este de Europa. Se debe insistir en las medidas para controlar el consumo de tabaco y prevenirlo, tales como la prohibición del consumo en lugares públicos, la prohibición real de la publicidad directa e indirecta, la reducción del cultivo, o el incremento de precios. Estas acciones se deben diseñar, coordinar y desarrollar en y desde los diferentes sectores involucrados en la lucha contra el tabaco, con la participación de redes civiles impulsadas desde los diferentes niveles administrativos (local, regional, nacional) con la decisiva participación de organismos y organizaciones supranacionales.


Tobacco is the most important preventable cause of mortality in European countries, accounting for over half a million deaths per year. A review is presented on the epidemiology of tobacco smoking in Europe, using a comprehensive approach on the health effects of smoking, the prevalence of tobacco consumption, and its evolution in the past decade. Tobacco industry efforts to promote and maintain smoking through production and princing are also reviewed. Thirty out of every 100 European adults smoke everyday and one of every ten adults smokers will die from tobacco smoking; a higher ratio of 1:15 is found in Eastern Europe. The prevalence of smokers is decreasing among young adults in some European countries, while it is increasing among young women in Southern and Eastern Europe. Smoking cessation and prevention interventions should be implemented, such as banning smoking in public areas, banning direct and indirect advertising of tobacco products, crop reduction, and rising cigarette prices. These interventions should be designed, coordinated, and developed by and among the different sectors involved in tobacco control initiatives, together with social network at the local, regional, and national levels, with the support of national and international organizations.


Assuntos
Adolescente , Adulto , Feminino , Humanos , Masculino , Fumar/epidemiologia , Causas de Morte , Custos e Análise de Custo , Europa (Continente)/epidemiologia , Prevalência , Indústria do Tabaco/economia , Indústria do Tabaco/estatística & dados numéricos , Poluição por Fumaça de Tabaco/estatística & dados numéricos
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa